AMCP Partnership Forum: enabling the exchange of clinical and economic information pre-FDA approval.

Academy of Managed Care Pharmacy. J Manag Care Pharm. 2017;23(1):105-112.

CMS to test enhanced medication therapy management model: aims for greater use of pharmacists, cost savings, and better outcomes.

Barlas S. P T. 2016;41(7):423-441.

The impact of comprehensive case management on HIV client outcomes.

Brennan-Ing M, et al. PLoS One. 2016;11(2):e0148865.

Assessment of the level of satisfaction and unmet data needs for specialty drug formulary decisions in the United States.

Choi Y, Navarro RP. J Manag Care Spec Pharm. 2016;22(4):368-375

Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results.

Eron J, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAX0205LB.

Expenditures for persons living with HIV enrolled in Medicaid, 2006-2010.

Fleishman JA, et al. J Acquir Immune Defic Syndr. 2016;72(4):408-415.

A phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48.

Gallant J, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAB0105LB.

What are the incentives for Medicare prescription drug plans to consider long-term outcomes and cost?

Hung A, Perfetto EM. J Manag Care Spec Pharm. 2016;22(7):773-778.

A qualitative study of barriers to and facilitators of optimal engagement in care among PLWH and substance use/misuse.

Kuchinad KE, et al. BMC Res Notes. 2016;9:229.

Phase III Sword 1&2: switch to DTG+RPV maintains virologic suppression through 48 wks.

Lllibre JM, et al. 24th Conference on Retroviruses and Opportunistic Infections; February 13−16, 2017; Seattle, WA. Abstract 44LB.

The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines.

Malone DC. J Manag Care Pharm. 2005;11(suppl 4):S7-S10.

Demographic, insurance, and health characteristics of newly enrolled HIV-positive patients after implementation of the Affordable Care Act in California.

Satre DD, et al. Am J Public Health. 2016;106(7):1211-1213.

Dual therapy with darunavir/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized ANDES study.

Sued O, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAB0106LB.

Single- versus multiple-tablet HIV regimens: adherence and hospitalization risk.

Sutton SS, et al. Am J Manag Care. 2016;22(4):242-248.

Systemic market and organizational changes: impact on P&T committees.

Vogenberg FR, et al. P T. 2017;42(1):28-32.